|
| | Molnupiravir Basic information |
| Product Name: | Molnupiravir | | Synonyms: | Uridine, 4-oxime, 5'-(2-methylpropanoate), (4Z)-;Molnupiravir-001-QA;Molnupiravir D7Q: What is
Molnupiravir D7 Q: What is the CAS Number of
Molnupiravir D7;MolnupiravirQ: What is
Molnupiravir Q: What is the CAS Number of
Molnupiravir Q: What is the storage condition of
Molnupiravir;((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate;Molnupiravir;Molnupiravir In-House;((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (Molnupiravir Impurity) | | CAS: | 2492423-29-5 | | MF: | C13H19N3O7 | | MW: | 329.31 | | EINECS: | | | Product Categories: | | | Mol File: | 2492423-29-5.mol |  |
| | Molnupiravir Chemical Properties |
| density | 1.62±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (303.67 mM; Need ultrasonic) | | pka | 6.71±0.20(Predicted) |
| | Molnupiravir Usage And Synthesis |
| Description | Prodrug of antiviral nucleoside analog; inhibits SARS-CoV, SARS-CoV-2 and MERS-CoV infection. | | Definition | ChEBI: Molnupiravir is a nucleoside analogue that is N(4)-hydroxycytidine in which the 5'-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N(4)-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19. It has a role as a prodrug, an anticoronaviral agent and an antiviral drug. It is a nucleoside analogue, an isopropyl ester and a ketoxime. It is functionally related to a N(4)-hydroxycytidine. | | Biological Activity | Molnupiravir is a broad-spectrum antiviral prodrug of the nucleoside analog β-D-N4-hydroxycytidine (NHC). It competes predominantly with CTP for incorporation; it induces lethal viral mutagenesis by increasing G to A and C to U transition mutations without inhibition of RNA synthesis in replicating coronaviruses, which prevents the development of viral resistance. In primary airway epithelial cell cultures, Molnupiravir dose-dependently inhibits SARS-CoV-2 infectious virus production; it also inhibits MERS-CoV and SARS-CoV with EC50 values in the submicromolar range. In mice infected with SARS-CoV or MERS-CoV, it improves pulmonary function, and reduces virus titer and body weight loss. Molnupiravir also displays in vivo efficacy against seasonal and pandemic influenza A shed virus. It is orally bioavailable. | | storage | Store at -20°C |
| | Molnupiravir Preparation Products And Raw materials |
|
